Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would be more inspired if the executive team showed similar commitment - they may not have a choice about the R/S if trading volume continues on pace, without a corresponding price appreciation.
Partnership would be welcome.
Petkevich Misha (Director)bought 167,000 shares @0.58 on Oct 28. It doesn't look like they're planning a R/S.
On the fence - they sold ATM during last data release, and don’t have a strategy to support common shares at this level. They need funding, and have no milestones for the next 12 months.
7 more days below $1.00 earns them delisting notice, and I can’t tell if new management has the balls not to R/S.
$CWBR 20/50/200 Buying the Dip here, anyone else?
https://finviz.com/quote.ashx?t=CWBR&ty=c&p=d&b=1
The use of Mitochonridal medicine is very appropriate for weight gain, diabetes and all of the symptoms associated with Metabolic Syndrome.
These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.
One major cause are various stressors that put the body in more or less permanent stress state. Cortisol, adrenaline, prostaglandins, reactive oxygen species, estrogens through aromatization of androgens etc. take their toll on the body.
The mitochondria is forced to switch to burning fat, muscle etc. often because these reactive oxygen species create too much hydrogen peroxide which blocks glucose intake into the mitochondria and obstructs that pathway of creating ATP. This is the cause of insulin resistance and accordingly diabetes.
With the use of mitochondrial enzymes there is a good chance of eliminating the effects of stress (and more specifically the build up of hydrogen peroxide).
An example of what is going on from Dr. Chris Masterjohn PhD.
Looks like your YouTube video was wrong so far
And dropped lime a rock
COHBAR ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 1A/1B STUDY OF CB4211 UNDER DEVELOPMENT FOR NASH AND OBESITY
CB4211 was well-tolerated and appeared safe with no serious adverse events
Robust reductions in ALT and AST
Reduction in glucose and trend towards body weight reduction
Company to host conference call and webcast at 5:00 p.m. ET
MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced topline results from the multi-center, randomized, double-blind, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for nonalcoholic steatohepatitis (NASH) and obesity. The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events. Evaluation of the exploratory pharmacodynamic endpoints from the Phase 1b stage of the study comparing CB4211 to placebo demonstrated robust and significant reductions in key biomarkers of liver damage, ALT and AST, a significant decrease in glucose levels, and a trend towards lower body weight after four weeks of treatment. Both the CB4211 and placebo groups had substantial reductions in liver fat content compared to baseline.
Key findings from the topline data of the Phase 1b portion of the study are summarized below.
Biomarker CB4211 (25 mg)
(n = 11) Placebo
(n = 9)
Difference from
Placebo
ALT
(% reduction from baseline)
-21% 4% -25*
Proportion of subjects with >17 U/L decrease in ALT ( 1)
27% 11% 16%
AST
(% reduction from baseline)
-28% -11% -17%*
Glucose
(% reduction from baseline) -6% 0% -6%*
ALT: Alanine aminotransferase. AST: Aspartate aminotransferase.
*Statistically significant versus placebo, p<0.05 by unpaired t test
(1) A decrease in ALT by 17 U/L or more is significantly associated with histologic response in NASH (Loomba R et al. Gastroenterology, 2019; 156 (1): 88-95)
MRI-PDFF Data CB4211 (25 mg)
(n = 11) Placebo
(n = 9)
Baseline Liver Fat Content (LFC)
21.1% 15.9%
Percent Reduction in LFC (Absolute)
-5.03%
-4.88%
Proportion of Responders Achieving >30% Relative Reduction in LFC 36% 33%
MRI-PDFF: Magnetic resonance imaging – proton density fat fraction.
“The results from the Phase 1b CB4211 study are promising,” stated Dr. Rohit Loomba, MD, MHSc, Professor of Medicine, Director, NAFLD Research Center, and Director of Hepatology, University of California at San Diego. “Demonstrating significant reductions of this magnitude in both serum ALT and AST relative to placebo after only four weeks suggests a potential for improvement in liver health if we continue to see further improvements over a longer period of time in patients with NASH. Improvements in serum ALT and AST are key predictors of histologic response independent of liver fat change; CB4211 shows great promise as a potential candidate for further development in NASH for this growing epidemic of silent and progressive liver disease.”
The results from both portions of the study indicate that CB4211 was well-tolerated and appeared safe with no serious adverse events. The only adverse events occurring in >10% of subjects receiving CB4211 in the four-week Phase 1b portion of the study were transient and generally mild to moderate injection site reactions.
“We are pleased with the positive outcome of our first human trial of CB4211 and look forward to working with disease experts to explore the next steps for our CB4211 program,” stated Dr. Joseph Sarret, CohBar’s Chief Executive Officer. “These impressive results validate our novel approach of using the mitochondrial genome as a valuable source of potential therapeutic peptides to treat serious systemic diseases.”
The Phase 1a stage of the study was a double blind, placebo-controlled single ascending dose and multiple ascending dose assessment of safety, tolerability, and pharmacokinetics over one week in 65 healthy adults, to select the most appropriate dose for the Phase 1b stage. The Phase 1b study was a randomized, double-blind, placebo-controlled evaluation of a 25 mg dose of CB4211 given once daily by subcutaneous injection for four weeks in 20 obese subjects with nonalcoholic fatty liver disease (NAFLD). The primary endpoints were safety and tolerability, with a secondary endpoint of pharmacokinetics, and exploratory endpoints of changes in liver fat, body weight, and biomarkers relevant to NASH, obesity, and metabolic disease. Subjects were required to have a minimum of 10% liver fat at enrollment, and to stay in the clinical study unit during the four weeks of treatment. This study was conducted at four sites.
CB4211 is the first mitochondria based therapeutic to enter clinical testing. Mitochondria based therapeutics are an emerging class of drugs based on novel analogs of peptide sequences discovered by CohBar scientists in the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body.
The company is continuing to analyze the data and plans to present additional results and analyses at a future scientific meeting.
Conference Call:
Date: August 10, 2021
Time: 5:00 p.m. ET (2:00 p.m. PT)
Conference Audio
Dial-in U.S. and Canada: (877) 300-8521
Dial-in International: (412) 317-6026
Conference ID No.: 10159293
Slide Presentation
Please visit https://us02web.zoom.us/j/84796437737?pwd=R2t0eEFRVDVlVDVZMTdhT0pGWVVsUT09 and enter password CWBR, or
Go to www.cohbar.com and click on CohBar Q2 2021 Investor Presentation at the top of homepage.
For individuals participating in the Investor Call and Slide Presentation, please call into the conference audio and log into Zoom approximately 10 minutes prior to its start. Please note, no audio will be available through Zoom.
An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on August 10, 2021, through 11:59 p.m. Eastern Time on August 31, 2021. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 10159293. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period.
About CB4211
CB4211 is a first-in-class mitochondria based therapeutic (MBT) that recently completed a Phase 1a/1b clinical study for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP), which was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic collaborators. NASH has been estimated to affect as many as 30 million adults in the U.S., and there is currently no approved treatment for the disease.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company’s lead compound, CB4211, recently completed a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs with the most advanced being CB5138-3 for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, which is currently in IND-enabling studies. The preclinical programs also include the CB5064 Analogs for acute respiratory distress syndrome (ARDS) including COVID-19 associated ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.
For additional company information, please visit www.cohbar.com .
Forward-Looking Statements
This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com .
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Contacts:
Jordyn Tarazi
Director of Investor Relations
CohBar, Inc.
(650) 445-4441
Jordyn.tarazi@cohbar.com
CWBR v HEPA
Similar concepts, similar undervaluation.
Anyone with a better knowledge of the science want to opine on which is better?
NASH competition for CWBR
https://finance.yahoo.com/news/hepion-pharmaceuticals-announces-positive-topline-120000659.html
HEPA hits all P2 targets. Well financed with over $100m on balance sheet.
A better deal than CWBR?
CWBR stock looks like AVXL did 5 years ago...
Platform drugs with multiple applications
Focused on true healing at the cellular level.
But CWBR P1 not completed yet.
AVXL basically marked time for 5 years until this year when quality p2 trial results started to be available. then up 10x
5 years is longer than many can wait with little return.
I like what I see here, but wonder if I still have the patience or the lifespan to wait.
Hat tip to good friend who sees clearly.
I've been buying some, going to wait then add or duck tail and run.
CWBR just upgraded to a BUY @$8 per share by Agesis. This stock is heavily shorted only 15,000 share left to short at this time. Time to buy?
OK, I give. What are you talking about? Serious Question.
Looks who it is. Same face different name.
Wrong this is a very bad company
4 Penny Stocks That Went Big In October; 1 Up 134%
$CWBR $GNC $KSHB $ZEST
https://www.transparenttraders.me/2019/10/4-penny-stocks-that-went-big-in-october.html
It's too early to know this since no clinical trials have been started yet. I've learned the hard way that entering biotech too early is usually a mistake.
https://clinicaltrials.gov/ct2/results?cond=&term=CohBar+Inc&cntry=&state=&city=&dist=&Search=Search
Please correct me if I'm wrong and they've at least done a phase I safety trial in another country. I've not had time to do the research and it appears you may have done so.
Thanks...
In Reply to 'hedgeclipper'
IMO a buying opportunity. All the fundamentals still there for CohBar to be the next (and best) NASH play.
IMO a buying opportunity. All the fundamentals still there for CohBar to be the next (and best) NASH play.
Guess it is your typical sell the news.
It will be very interesting to see how todays presentation affects the share price this week.
Best of breed NASH therapeutic close to human clinicals. NASH is the hottest area in biotech. See Nimbus/Gilead deal for the kind of numbers that are possible for CohBar. Massive upside here folks.
CWBR moved to the Nasdaq from the OTC:
http://otce.finra.org/DLDeletions
CohBar Announces Approval for Listing on the NASDAQ Capital Market
Dec 13, 2017
OTC Disclosure & News Service
-
NASDAQ Trading to Begin on December 15, 2017 Under Existing Ticker Symbol CWBR
CohBar Announces the Appointment of Dr. John Amatruda to its Board
Per their conference call. They company had met all up listing requirements and had started the process.
It generally takes 4-6 weeks to process a listing application. This time frame is variable and may be shortened considerably, if the application raises no issues and the company responds to staff comments.
Week 1. Company submits application for listing and NASDAQ listing Qualifications staff begins its review.
Week 2-3. Staff completes its preliminary review and prepares comment letter.Week 3-4. Company addresses any issues raised by staff.
Week 5-6. Staff completes their review and company is approved for listing
by these guidelines guessing they will announce up list in the next two weeks.
KSS, MD, PhD? @KSSMDPhD · Nov 17
A mitochondrially-derived peptide owned by $CWBR recently shown to abate completely any toxicity to cultured neuronal cells conferred by amyloid proteins. And at low therapeutic concentration. Next step: animal model
guessing this will be announced after Nasdaq uplist in a couple weeks.
Thank you. I have been interested in the persuasion and Dilbert commic strip Scott Adams is a professional persuader. He is on twitter. I bring this up based upon what you do for a living. I have just finished reading his book Win Bigly.
Thinks I never thought about. So there is also a master persuader out there that has written several books:
https://www.amazon.com/gp/product/150822319X/ref=oh_aui_detailpage_o00_s00?ie=UTF8&psc=1
Imagine being a litigator and being armed with this !!
Regards
Additionally they added it will be done this year.
Per conference call they are currently in the process of uplisting to Nadaq!
Details for the Conference Call and Slide Presentation:
Date: November 13, 2017
Time: 2:00 p.m. (Pacific Time)
Audio, Dial-in U.S. and Canada: 1-888-599-8667
Audio, Dial-in International: 1-719-325-2494
Conference ID# 643238
Slide Presentation – go to www.webex.com, click on the ‘Join’ button and enter Meeting Number 921656999 and Password Q3Call.
If the company can maintain this price through the end of the year they should be eligible to uplist.
CohBar, Inc. to Announce Third Quarter 2017 Financial Results and Host Conference Call for Shareholders on November 13, 2017
Very interesting, thanks!
BTW: I wonder if Carbon 60 (C60) is anything worth looking into?
What's a Safe Obesity Pill Worth? "There’s a gold mine available”- Bloomberg
https://www.bloomberg.com/news/articles/2017-07-04/why-big-pharma-is-struggling-to-profit-from-the-obesity-epidemic
$CWBR
Yes Hopefully sooner than later uplisting. Extremely important. The website is being revised.
Regis999 in your discussions with the company did you happen to discuss uplisting to Nasdaq? Seems at this price and with the companies potential it would be a no brainer.
Thanks for all your help.
Thank you Sir! Will do
Here is the near term CWBR catalyst
The company is set to make a presentation at The Liver Meeting 2017 slated for October 20-24, 2017 in Washington D.C.
Go look at page 16 slides in company presentation "CB4209 reduces Liver Fat
(Steatosis)--See slide 3
Nice job Codaras !! Ready for an elevator pitch?
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
93
|
Created
|
09/20/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |